Scientists identify why some heart rhythm drugs heighten risks when sodium levels drop
Peer-Reviewed Publication
In recognition of Heart Health Month, we’re spotlighting the importance of cardiovascular wellness. From risk factors and prevention to innovative treatments, we’re exploring the science and stories shaping heart health today.
Updates every hour. Last Updated: 21-Jul-2025 06:11 ET (21-Jul-2025 10:11 GMT/UTC)
New research explains how low levels of the electrolyte sodium in the blood can disrupt the timing of the heartbeat in patients taking widely used rhythm-control medications such as flecainide, which is commonly prescribed for atrial fibrillation and other fast or irregular heart rhythms.
Researchers at Sutter Health and colleagues at Stanford University tested the performance of the American Heart Association’s Predicting Risk of CVD Events (PREVENT) equations in the six largest Asian subgroups as well as in Mexican and Puerto Rican Hispanic subgroups. The findings, published in JAMA Cardiology, showed the PREVENT equations accurately predicted cardiovascular disease, atherosclerotic CVD (ASCVD) and heart failure events across broad, self-identified Asian and Hispanic patient populations.
In order to elucidate the mechanisms underlying NET activation and its impact on MIRI, Hongru Zhang/Senlei Xu of Nanjing University of Chinese Medicine (NJUCM), along with Yanfei Mo of Pukou Hospital of Chinese Medicine, confirm that the generation of NETs by neutrophils exacerbates microvascular endothelial cell injury, thereby worsening MIRI.